Ranolazine reduces atrial fibrillatory wave frequency

ConclusionRanolazine is associated with lower AF DF but no change in OI or fibrillatory wave amplitude. Prospective trials are needed to evaluate ranolazine's potential as a novel antiarrhythmic drug for AF.
Source: Europace - Category: Cardiology Source Type: research